



UNITED STATES ~~U~~ PART OF COMMERCE
United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
(1)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

100311-3
11/10/2003
JEREMY COLEMAN
1425 14TH ST. NW, #301
WASH. DC 20004

EXAMINER	
ART UNIT	PAPER NUMBER

DATE MAILED:

30

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary	Application No.	Applicant(s)
	09/068,528	KOIZUMI ET AL.
	Examiner Manjunath N Rao	Art Unit 1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 13 September 2001.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1,5,8 and 15-20 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1,5,8 and 15-20 is/are rejected

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17 2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____	6) <input type="checkbox"/> Other: _____

DETAILED ACTION

Continued Prosecution Application

1. The request filed on 9-13-01 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 09/068,528 is acceptable and a CPA has been established. An action on the CPA follows.

2. Claims 1, 5, 8, 15-20 are still at issue and are present for examination. Applicants' arguments filed on 9-13-01, paper No.29, have been fully considered and are deemed to be persuasive to overcome some of the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claim 1 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 1, in lines 7-8, recited the phrase "a freeze-dried product of the cells" in duplicate. Examiner requests an amendment to claim 1 such that the above phrase is recited only once.

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. Claims 1, 5, 8 and 15-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Maruyama et al. (EP 0 553 821 B1, dated 3-19-1997) in view of Weissborn et al. (J. Bacteriol., 1994, Vol. 176:2611-2618). See previous Office action for rejection.

In response to the previous Office action, applicants have traversed the above rejection arguing that they have amended the claim to specify that the "treated product of culture broth" and that claim 1 as amended does not include glucose-1-phosphate and that the Examiner's position is plainly incorrect since the "treated product of culture broth" is simply used an enzyme source. Examiner respectfully disagrees. While applicants have amended claim 1 to more specifically point out the "treated product of culture broth", they continue to include in the group mechanically disrupted product of cell (i.e., all cell lysates and their concentrates). Such treated products of the culture still encompass glucose-1-phosphate. All bacterial cells will have glucose-1-phosphate present in them as it is the main product of glycogen or starch breakdown and also the intermediate product of tricarboxylic acid cycle. Furthermore glucose-1-phosphate and glucose-6-phosphate are reversibly interconvertible. While applicants claim that they are using the "treated product of culture broth" as simply as a source of enzyme, the claim as written does not convey the same. Applicants agree that trace amounts of glucose-1-phosphate may exist in the treated product of the culture broth, however, a sugar nucleotide cannot be produced by using such trace amounts of glucose-1-phosphate (see foot note in applicant's response). This argument is also still not persuasive to overcome the above rejection because, applicants are not using the treated product as such with trace amounts of glucose-1-phosphate, they are concentrating it or drying it which does increase the concentration of glucose-1-phosphate several folds and could potentially become a substrate. Therefore the above rejection is maintained.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Manjunath Rao whose telephone number is (703) 306-5681. The Examiner can normally be reached on M-F from 6:30 a.m. to 3:00 p.m. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, P.Achutamurthy, can be reached on (703) 308-3804. The fax number for Official Papers to Technology Center 1600 is (703) 305-3014.

Art Unit: 1652

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Manjunath N. Rao, Ph.D.
November 1, 2001

Manjunath N. Rao, Ph.D.

11/01/01